Shares of Cardlytics Inc (NASDAQ:CDLX) have been assigned an average recommendation of “Buy” from the seven analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $24.40.

CDLX has been the subject of a number of research analyst reports. KeyCorp cut their price target on shares of Cardlytics from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Wednesday, August 15th. Bank of America reissued a “hold” rating and issued a $22.00 price target on shares of Cardlytics in a report on Friday, August 17th. Zacks Investment Research downgraded shares of Cardlytics from a “hold” rating to a “sell” rating in a report on Tuesday, August 21st. Finally, SunTrust Banks reissued a “buy” rating and issued a $27.00 price target on shares of Cardlytics in a report on Tuesday.

In other Cardlytics news, COO Lynne Marie Laube sold 1,349 shares of the company’s stock in a transaction dated Friday, August 17th. The shares were sold at an average price of $20.66, for a total transaction of $27,870.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Scott D. Grimes sold 1,445 shares of the company’s stock in a transaction dated Friday, August 17th. The shares were sold at an average price of $20.66, for a total transaction of $29,853.70. The disclosure for this sale can be found here. Insiders have sold 5,194 shares of company stock valued at $107,308 over the last ninety days.

Hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System purchased a new stake in Cardlytics during the first quarter valued at about $122,000. Schwab Charles Investment Management Inc. purchased a new stake in Cardlytics during the second quarter valued at about $214,000. California Public Employees Retirement System purchased a new stake in Cardlytics during the first quarter valued at about $146,000. Spark Investment Management LLC purchased a new stake in Cardlytics during the first quarter valued at about $150,000. Finally, Barclays PLC purchased a new stake in Cardlytics during the first quarter valued at about $175,000. 49.62% of the stock is owned by institutional investors.

NASDAQ CDLX traded up $2.21 on Friday, reaching $27.69. The company’s stock had a trading volume of 10,975 shares, compared to its average volume of 240,691. Cardlytics has a twelve month low of $11.10 and a twelve month high of $26.77. The company has a current ratio of 2.24, a quick ratio of 2.24 and a debt-to-equity ratio of 1.29. The company has a market capitalization of $514.51 million and a price-to-earnings ratio of -3.34.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Tuesday, August 14th. The company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.53) by $0.32. The business had revenue of $35.57 million during the quarter, compared to analyst estimates of $34.89 million. Cardlytics’s revenue for the quarter was up 8.4% on a year-over-year basis. research analysts predict that Cardlytics will post -2.39 earnings per share for the current year.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

See Also: Exchange-Traded Funds (ETFs)

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.